Announcement

Collapse
No announcement yet.

MIM-D3 by Mimetogen Pharmaceuticals

Collapse
This topic is closed.
X
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • MIM-D3 by Mimetogen Pharmaceuticals

    All,

    Currently, there is no FDA-approved medication that specifically targets evaporative dry eye.

    Mimetogen Pharmaceuticals has positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles.

    MIM-D3, or known/labeled as "Tavilermide". Mimetogenís lead compound is currently being evaluated in a multi-center Phase 3 clinical study in the United States for the treatment of dry eye syndrome. Development is moving along...
Working...
X